A detailed history of Nissay Asset Management Corp transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Nissay Asset Management Corp holds 16,101 shares of ALNY stock, worth $4.58 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
16,101
Previous 15,577 3.36%
Holding current value
$4.58 Million
Previous $2.33 Million 68.11%
% of portfolio
0.03%
Previous 0.02%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$143.31 - $247.0 $75,094 - $129,428
524 Added 3.36%
16,101 $3.91 Million
Q1 2024

May 15, 2024

BUY
$146.51 - $198.2 $46,736 - $63,225
319 Added 2.09%
15,577 $2.33 Million
Q4 2023

Feb 14, 2024

BUY
$151.41 - $196.57 $73,433 - $95,336
485 Added 3.28%
15,258 $2.92 Million
Q3 2023

Nov 14, 2023

BUY
$170.77 - $211.65 $91,703 - $113,656
537 Added 3.77%
14,773 $2.62 Million
Q2 2023

Aug 14, 2023

SELL
$185.01 - $212.05 $51,802 - $59,374
-280 Reduced 1.93%
14,236 $2.7 Million
Q1 2023

May 15, 2023

SELL
$182.66 - $235.53 $35,436 - $45,692
-194 Reduced 1.32%
14,516 $2.91 Million
Q4 2022

Feb 14, 2023

SELL
$185.53 - $241.31 $8,905 - $11,582
-48 Reduced 0.33%
14,710 $3.5 Million
Q3 2022

Nov 14, 2022

BUY
$138.54 - $232.0 $77,028 - $128,992
556 Added 3.91%
14,758 $2.95 Million
Q2 2022

Aug 15, 2022

BUY
$120.42 - $169.29 $21,555 - $30,302
179 Added 1.28%
14,202 $2.07 Million
Q1 2022

May 16, 2022

BUY
$127.18 - $173.91 $49,091 - $67,129
386 Added 2.83%
14,023 $2.29 Million
Q4 2021

Feb 14, 2022

BUY
$159.56 - $209.29 $59,196 - $77,646
371 Added 2.8%
13,637 $2.31 Million
Q3 2021

Nov 10, 2021

BUY
$169.75 - $207.73 $324,731 - $397,387
1,913 Added 16.85%
13,266 $2.51 Million
Q2 2021

Aug 13, 2021

BUY
$128.63 - $176.89 $34,730 - $47,760
270 Added 2.44%
11,353 $1.93 Million
Q1 2021

May 11, 2021

SELL
$126.83 - $175.69 $36,653 - $50,774
-289 Reduced 2.54%
11,083 $1.57 Million
Q4 2020

Feb 08, 2021

SELL
$122.97 - $147.0 $20,658 - $24,696
-168 Reduced 1.46%
11,372 $1.48 Million
Q3 2020

Oct 20, 2020

BUY
$121.19 - $165.49 $57,444 - $78,442
474 Added 4.28%
11,540 $1.68 Million
Q2 2020

Jul 27, 2020

BUY
$104.21 - $156.44 $151,625 - $227,620
1,455 Added 15.14%
11,066 $1.64 Million
Q1 2020

May 05, 2020

BUY
$93.12 - $133.99 $37,248 - $53,596
400 Added 4.34%
9,611 $1.05 Million
Q4 2019

Feb 14, 2020

SELL
$74.51 - $124.23 $6,109 - $10,186
-82 Reduced 0.88%
9,211 $1.06 Million
Q3 2019

Nov 14, 2019

BUY
$70.9 - $87.82 $106,208 - $131,554
1,498 Added 19.22%
9,293 $747,000
Q2 2019

Aug 07, 2019

BUY
$65.86 - $92.79 $15,345 - $21,620
233 Added 3.08%
7,795 $566,000
Q1 2019

May 03, 2019

BUY
$72.76 - $93.45 $28,667 - $36,819
394 Added 5.5%
7,562 $707,000
Q4 2018

Feb 06, 2019

BUY
$62.67 - $88.33 $31,773 - $44,783
507 Added 7.61%
7,168 $523,000
Q3 2018

Oct 30, 2018

BUY
$87.52 - $122.67 $22,667 - $31,771
259 Added 4.05%
6,661 $583,000
Q2 2018

Aug 08, 2018

SELL
$88.31 - $107.8 $448,173 - $547,085
-5,075 Reduced 44.22%
6,402 $631,000
Q1 2018

May 14, 2018

BUY
$115.92 - $148.54 $18,547 - $23,766
160 Added 1.41%
11,477 $1.37 Million
Q4 2017

Feb 14, 2018

BUY
$114.49 - $139.98 $1.3 Million - $1.58 Million
11,317
11,317 $1.44 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $35B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Nissay Asset Management Corp Portfolio

Follow Nissay Asset Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nissay Asset Management Corp , based on Form 13F filings with the SEC.

News

Stay updated on Nissay Asset Management Corp with notifications on news.